An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

Key points Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show striking effectiveness across diverse populations at high risk for HIV.

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines durings the world's most influential meeting on HIV research and its ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

While a vaccine to prevent HIV still is needed, some experts say the shot made by Gilead Sciences — a drug called lenacapavir — could be the next best thing.